Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.
The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice.
Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria.
The market for atopic dermatitis therapies is dominated by topical corticosteroids, but is poised to change with the recent approvals of dupilumab and crisaborole, as well as other drugs in clinical development.